Quality Expertise Tailored to Your Industry
Pharmaceutical and biotechnology are not monolithic. The quality challenges facing a gene therapy startup differ fundamentally from those of a commercial oral solid dosage manufacturer. We bring phase- and modality-appropriate expertise to every engagement.
Pharmaceutical Manufacturing
Commercial-scale compliance without sacrificing operational efficiency.
Modalities & Sectors
Small molecule drug products, oral solid dosage, sterile injectables, topicals, and combination products.
Commercial pharmaceutical manufacturers operate under intense regulatory scrutiny across multiple global markets. Our consultants have led quality programs at commercial-scale facilities and understand the operational complexity of maintaining GMP compliance while meeting production demands.
Common Challenges We Address
- Multi-site quality system harmonization across domestic and international facilities
- Post-approval change management and regulatory filing strategy
- Annual product review programs and quality metrics reporting
- Supplier qualification and contract manufacturer oversight
- Data integrity remediation and 21 CFR Part 11 compliance
Biotechnology & Biologics
Navigating the unique complexity of living systems at scale.
Modalities & Sectors
Monoclonal antibodies, recombinant proteins, cell and gene therapies, vaccines, and biosimilars.
Biologics manufacturing demands a quality framework that accounts for the inherent variability of living systems, the sensitivity of protein-based therapeutics, and the evolving regulatory landscape for biosimilars and novel modalities. We bring deep biologics-specific expertise to every engagement.
Common Challenges We Address
- Biologic process characterization and comparability studies
- Cell therapy and gene therapy GMP program development
- BLA and MAA submission strategy for novel biologics
- Biosimilar development quality strategy and regulatory pathway
- Viral safety and adventitious agent testing programs
Clinical-Stage Companies
Building the quality foundation that supports your path to approval.
Modalities & Sectors
Early-phase biotech, virtual pharma companies, academic spinouts, and venture-backed startups.
For companies in Phase I through Phase III, the quality decisions made today shape the regulatory pathway for years to come. We help clinical-stage organizations build quality systems that are appropriately scaled for their current stage while designed to grow with them toward commercialization.
Common Challenges We Address
- IND-enabling quality system design and implementation
- Phase-appropriate GMP program development
- CMC strategy and IND/CTA documentation
- Clinical supply quality oversight and batch release
- Pre-NDA/BLA quality readiness assessment
Contract Manufacturers & CDMOs
Quality systems that protect your clients and differentiate your business.
Modalities & Sectors
Drug substance and drug product CMOs, fill-finish specialists, analytical service providers, and full-service CDMOs.
Contract manufacturers and CDMOs face a dual compliance challenge: satisfying their own regulatory obligations while meeting the diverse quality expectations of a broad client base. We help CMOs and CDMOs build quality frameworks that are both audit-ready and operationally sustainable.
Common Challenges We Address
- Quality agreement development and client relationship management
- Multi-client quality system design and segregation strategies
- Technology transfer quality oversight and documentation
- Client audit preparation and hosting
- Capacity expansion and new modality qualification
Medical Devices & Combination Products
Bridging the quality requirements of drug and device regulation.
Modalities & Sectors
Prefilled syringes, autoinjectors, drug-eluting implants, inhaled drug-device combinations, and digital therapeutics.
Combination products and drug-device interfaces present unique regulatory complexity, requiring quality programs that satisfy both pharmaceutical GMP and device QSR/MDR requirements. Our team has navigated the intersection of these frameworks across prefilled syringes, drug-eluting devices, and digital health combinations.
Common Challenges We Address
- Combination product designation and regulatory pathway strategy
- Design controls and risk management per ISO 14971
- 21 CFR Part 820 / EU MDR quality system alignment
- Container closure integrity and extractables/leachables programs
- Post-market surveillance and complaint handling systems
Your industry. Your stage. Our expertise.
Every engagement starts with understanding your specific context — your product, your regulatory pathway, and where you are in your development journey. Let's have that conversation.